Atara Biotherapeutics Receives $38,500,000 Series B Financing

  • Feed Type
  • Date
    12/18/2013
  • Company Name
    Atara Biotherapeutics
  • Mailing Address
    2659 Townsgate Road Thousand Oaks, CA 91361
  • Company Description
    Our mission is to develop novel treatment options for patients with severe and life-threatening conditions that have been underserved by scientific innovation. We are investigating therapies targeting unique pathways to pause or reverse patients’ underlying diseases.
  • Website
    http://www.atarabio.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $38,500,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Proceeds will be used to accelerate the clinical development of Atara’s two lead programs, PINTA 745 and STM 434, which are expected to generate new clinical data within the next 18 months.
  • M&A Terms
  • Venture Investor
    Amgen Ventures
  • Venture Investor
    Celgene
  • Venture Investor
    Alexandria Real Estate Equities
  • Venture Investor
    DAG Ventures
  • Venture Investor
    Domain Associates
  • Venture Investor
    Kleiner Perkins Caufield & Byers